[144] QUEST DIAGNOSTICS INC SEC Filing

Rhea-AI Filing Summary

Form 144 filed for Quest Diagnostics (DGX) reports a proposed sale of common stock and recent related transactions. The notice shows an intended sale of 175 shares through Fidelity Brokerage Services with an aggregate market value of $32,729 and an approximate sale date of 09/24/2025 on the NYSE. The 175 shares were acquired by option exercise on 09/24/2025 with cash payment. The filing also discloses a separate sale on 09/23/2025 by Michael Prevoznik of 28,288 common shares for gross proceeds of $5,293,312.79. The filer certifies no undisclosed material adverse information and references Rule 10b5-1 procedures.

Positive

• Proper compliance with Rule 144 disclosure requirements including broker, share counts, market value and acquisition details
• Inclusion of representation that the seller does not possess undisclosed material adverse information and reference to Rule 10b5-1, which reduces regulatory uncertainty

Negative

• Recent large insider sale by Michael Prevoznik of 28,288 shares for $5,293,312.79 may raise questions about insider selling pressure or timing
• Limited context provided about the reason for the prior large sale or whether it was part of a pre-arranged trading plan

Insights

Securities Analyst

TL;DR: Routine Rule 144 notice showing a small scheduled sale and a recent sizable insider sale the day before.

The filing documents a proposed sale of 175 shares (aggregate value $32,729) via Fidelity and confirms acquisition by option exercise on the same date. Separately, an insider, Michael Prevoznik, sold 28,288 shares on 09/23/2025 for $5,293,312.79. From a market-impact perspective, the 175-share proposed sale is immaterial; the prior 28,288-share sale generated material proceeds but the filing contains no context on continuing selling intent or strategic rationale. The compliance statements and mention of Rule 10b5-1 are standard and reduce regulatory risk related to timing.

Corporate Governance Expert

TL;DR: Disclosure is procedurally complete but provides limited governance context about insider selling.

The form meets Rule 144 disclosure requirements by identifying broker, share counts, market value, and acquisition details (option grant dated 02/19/2018). The signature representation about no undisclosed material adverse information is included, and a 10b5-1 reference appears. However, the filing does not state whether the prior large sale was part of a pre-established trading plan or the filers ongoing intentions, which limits governance transparency for investors evaluating insider alignment with shareholders.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	175	32729.03	111823441	09/24/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/24/2025	Option Granted - 02/19/2018	Issuer			175	09/24/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Michael Prevoznik 500 Plaza Drive Secaucus NJ 07094	Common	09/23/2025	28288	5293312.79

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for Quest Diagnostics (DGX) report?

The form reports a proposed sale of 175 common shares via Fidelity with aggregate market value of $32,729 and notes a separate sale on 09/23/2025 of 28,288 shares for $5,293,312.79.

When are the reported sales expected to occur for DGX?

The proposed sale of 175 shares lists an approximate sale date of 09/24/2025; the other disclosed sale occurred on 09/23/2025.

How were the 175 shares being sold by the filer acquired?

The 175 shares were recorded as acquired by an option granted on 02/19/2018 and show a 09/24/2025 acquisition date with cash payment.

Who executed the prior large sale and what were the proceeds?

The prior sale was executed by Michael Prevoznik, selling 28,288 common shares on 09/23/2025 for gross proceeds of $5,293,312.79.

Does the Form 144 indicate any undisclosed material information?

The signer represents they do not know of any material adverse information about the issuer that has not been publicly disclosed.